Louise Hiller
A5091704063- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- AI in cancer detection
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Anorectal Disease Treatments and Outcomes
- Pelvic floor disorders treatments
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Urinary Tract Infections Management
- Blood Coagulation and Thrombosis Mechanisms
- Statistical Methods in Clinical Trials
University of Warwick
2016-2025
Coventry (United Kingdom)
2024
Amsterdam University of Applied Sciences
2024
The Netherlands Cancer Institute
2015
University Hospital Heidelberg
2015
University Medical Center Hamburg-Eppendorf
2015
Copenhagen University Hospital
2015
University of Copenhagen
2015
Universität Hamburg
2015
Heidelberg University
2015
Abstract Background There is increasing international interest in the concept of mental well-being and its contribution to all aspects human life. Demand for instruments monitor at a population level evaluate health promotion initiatives growing. This article describes development validation new scale, comprised only positively worded items relating different positive health: Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). Methods WEMWBS was developed by an expert panel drawing on...
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined efficacy of anthracyclines in adjuvant treatment early breast cancer.In NEAT, we compared four cycles epirubicin followed by cyclophosphamide, methotrexate, fluorouracil (CMF) with six CMF alone. In trial, CMF, eight alone every 3 weeks. primary end points were relapse-free overall survival. secondary adverse effects, dose intensity, quality life.The two trials included 2391 women cancer; median follow-up was 48...
The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment early breast cancer. We investigated prospectively predictive biomarkers anthracycline including HER2 TOP2A.
The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab standard neoadjuvant chemotherapy in HER2-negative early breast cancer.
Anthracyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in past decade. We aimed to assess safety efficacy of addition gemcitabine accelerated paclitaxel with epirubicin cyclophosphamide, also effect sequencing blocks cyclophosphamide (with or without gemcitabine).
A missense variant in GLP1R associated with lower fasting glucose levels and protective against T2D is risk of coronary heart disease, suggesting that agonists are not an unacceptable increase cardiovascular risk.
Associations between taxane-related sensory neuropathy (TRSN) and single-nucleotide polymorphisms (SNP) have previously been reported, but few replicated in large, independent validation studies. This study evaluates the association investigated SNPs TRSN, using genotype data from a of chemotherapy-related toxicity patients with breast cancer.
Abstract Aim Organ‐saving treatment for early‐stage rectal cancer can reduce patient‐reported side effects compared to standard total mesorectal excision (TME) and preserve quality of life. An optimal strategy achieving organ preservation longer‐term oncological outcomes are unknown; thus there is a need high trials. Method Can we S ave the rectum by watchful waiting or T rans A nal surgery following (chemo) R adiotherapy versus otal early RE ctal C ancer (STAR‐TREC) an international...
Evidence indicates that acquired resistance of cancers to chemotherapeutic agents can occur via epigenetic mechanisms. Down-regulation expression argininosuccinate synthetase (ASS1), the rate-limiting enzyme in biosynthesis arginine, has been associated with development platinum ovarian cancer treated platinum-based chemotherapy. The aim present study was analyse regulation ASS1 tissue taken at diagnosis and relapse determine its significance as a predictor clinical outcome patients In...
The cytokine TGF-β acts as a tumor suppressor in normal epithelial cells and during the early stages of tumorigenesis. During malignant progression, cancer can switch their response to use this potent oncogenic factor; however, mechanistic basis for is poorly understood. Here we demonstrate that downregulation disabled homolog 2 (DAB2) gene expression via promoter methylation frequently occurs human squamous cell carcinomas (SCCs) an independent predictor metastasis poor prognosis....
There is a need to improve prediction of response chemotherapy in breast cancer order clinical management and this may be achieved by harnessing computational metrics tissue pathology. We investigated the association between quantitative image derived from analysis digital pathology slides women with who received neoadjuvant chemotherapy. digitised sections both diagnostic surgical samples tumours 768 patients enrolled Neo-tAnGo randomized controlled trial. subjected images systematic...
ObjectiveTo evaluate the impact of QuinteT Recruitment Intervention (QRI) on recruitment in challenging randomized controlled trials (RCTs) that have applied intervention. The QRI aims to understand difficulties and then implements "QRI actions" address these as proceeds.Study Design SettingA mixed-methods study, comprising (1) before-and-after comparisons rates numbers patients approached (2) qualitative case studies, including documentary analysis interviews with RCT...
506 Background: Adjuvant trastuzumab has significantly improved outcomes for HER2+ EBC pts, using the 12m duration empirically adopted from pivotal registration trials. A shorter could reduce toxicities and cost whilst providing similar efficacy. No reduced-duration trial to date demonstrated non-inferiority. Methods: PERSEPHONE is a randomised phase 3 non-inferiority comparing 6 trastuzumab, largest internationally. Mapping onto standard UK practice, all pts were eligible. Stratification by...